News
Filter Results
Displaying 1–10 of 489
-
Dec 2, 2024
ARPA-H award establishes multi-disciplinary consortium of industry experts to address current limitations and advance innovative technologies for vision-restoring whole eye transplantation.
Goal to bring light to those who are blind through first-ever successful vision recovery in six whole eye transplants in humans by 2030.
-
Nov 14, 2024
Strengthening research in retinal disease with record-breaking $19.8 million investment in innovative projects targeting vision loss worldwide.
-
Nov 13, 2024
Atsena’s LCA1 Gene Therapy Licensed by Nippon Shinyaku for Markets in US and Japan
The companies are planning a Phase 3 clinical trial for the promising gene therapy.
-
Oct 30, 2024
BlueRock’s Photoreceptor Cell Therapy to Move into Clinical Trial
The Foundation funded Dr. David Gamm for development of the induced pluripotent stem cell approach to be used in the trial.
-
Oct 29, 2024
Kiora Receives Authorization for Phase 2 Clinical Trial of its Photoswitch for Advanced RP
The 36-participant trial will take place at multiple sites in Australia.
-
Oct 25, 2024
The RD Fund Announces Ocuphire Pharma’s Acquisition of Opus Genetics
The resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD).
-
Oct 23, 2024
Opus Genetics, Ocuphire Merger to Boost Advancement of Several IRD Gene Therapies
Merger will provide additional capital for gene therapy development.
-
Oct 18, 2024
MicroRNA Breakthroughs: Paving the Way for Vision Restoration
Researchers funded by the Foundation Fighting Blindness are developing microRNA-based therapies for inherited retinal diseases, building on recent Nobel Prize-winning discoveries.
-
Oct 11, 2024
Safety Clinical Trial Launched for Usher Syndrome 3 Drug
Researchers hope the molecule will slow the vision and hearing loss associated with USH3.
-
Oct 7, 2024
Leber Congenital Amaurosis Research Advances
Recent developments in research on Leber congenital amaurosis